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Abstract 
Ventricular assist devices (VADs) are a life-saving form of mechanical circulatory support in 
heart failure patients. However, VADs have not yet reached their full potential due to the 
associated side effects (thrombosis, bleeding, infection) related to the activation and damage 
of blood cells and proteins caused by mechanical stress and foreign materials. Studies of the 
effects of VADs on leukocytes are limited, yet leukocyte activation and damage including 
microparticle generation can influence both thrombosis and infection rates. Therefore, the 
aim was to develop a multicolour flow cytometry assessment of leukocyte microparticles 
(LMPs) using ovine blood and the CentriMag VAD as a model for shear stress. Ovine blood 
was pumped for 6 hours in the CentriMag and regular samples analysed for haemolysis, 
complete blood counts and leukocyte microparticles by flow cytometry during three different 
pump operating conditions (low flow, standard, high speed). The high speed condition caused 
significant increases in plasma-free haemoglobin; decreases in total leukocytes, granulocytes, 
monocytes and platelets; increases in CD45
+
 LMPs as well as two novel LMP populations: 
CD11b
bright
/HLA-DR
-
 and CD11b
dull
/HLA-DR
+
, both of which were CD14
-
/CD21
-
. 
CD11b
bright
/HLA-DR
-
 LMPs appeared to respond to an increase in shear magnitude whereas 
the CD11b
dull
/HLA-DR
+
 LMPs significantly increased in all pumping conditions. We propose 
that these two populations are released from granulocytes and T cells, respectively, but 
further research is needed to better characterise these two populations.  
Key words:  
Flow cytometry, ovine, leukocyte, microparticle, shear stress, ventricular assist, CD11b, 
HLA-DR, CentriMag 
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Introduction 
Ventricular assist devices (VADs) are a life-saving form of mechanical circulatory support in 
refractory advanced heart failure patients, either as bridge to heart transplant or as destination 
therapy [1, 2]. However, VADs have not yet reached their full potential due to the associated 
side effects (stroke, bleeding, infection, and thrombosis) [3], related to the activation and 
damage to blood cells and proteins caused by mechanical stress and foreign materials.  
Studies of the effects of VADs on leukocytes are limited, yet leukocyte activation and 
damage can potentially influence both thrombosis and infection rates [4]. Clinical data 
demonstrate that VADs can cause an overall decrease in leukocyte counts [5], supported by 
in vitro studies using bovine blood, which show a device-specific decrease in viable 
leukocytes [6]. Activation of granulocytes [5] and CD4
+
 T cell apoptosis [7, 8], initiated by 
CD40-ligand (CD40L) induction [9, 10], have also been observed in VAD-patients. Studies 
on allosensitisation have shown that VAD-patients have hyperreactive B cells and increased 
levels of alloantibodies, probably caused by stimulation by activated T cells as evidenced by 
increased levels of soluble CD40L [10, 11]. Finally, microparticle (MPs) formation has been 
demonstrated in vitro [12, 13], and clinically [14-17], suggesting a use for them as predictive 
markers of adverse events [15, 17]. MPs are membrane vesicles released from many different 
cell types, through activation or apoptosis, with pro-inflammatory, pro-thrombotic, 
vasoconstrictive, and angiogenic effects [18-21]. Based on these effects it is evident that MPs 
can play a role in VAD-related thrombosis. Since MPs are mediators of cellular cross-talk 
[22], and MP levels are increased in patients with sepsis [23, 24] and parasitic infections [25], 
it is likely that MPs are involved in VAD-related infections. Since different cell types can 
release MPs, using lineage markers is important to determine the origin of the cell type. 
CD45 has been used to demonstrate leukocyte MPs (LMPs) in VADs in vitro [12, 13], and 
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CD11b or CD45 have been used to demonstrate LMPs in VAD-patient samples [14, 16]. 
Unfortunately, the studies linking microparticles to VAD-complications did not employ 
lineage markers [15, 17], so it remains unknown which parent cell type(s) are predictive of  
VAD-complications and there is a need for further studies to better identify MP cellular 
provenance and quantitative functional capacity before and after LVAD implantation [26]. 
The above mentioned examples demonstrate that VADs have an impact on leukocytes. 
However, the results are disarrayed by different device designs tested (including HeartMate 
XVE, HeartMate II, PVAD, HVAD, CentriMag, VentrAssist, Circulite, and RotaFlow), and a 
lack of lineage markers for leukocytes in the large animals used for pre-clinical studies, 
typically cows and sheep. This limits the ability to glean cell type specific effects during early 
in vitro and later in vivo testing.  
The ovine model is used commonly for in vivo testing of VADs [27-32], but there is a need 
for standardised in vitro methods to rapidly assess leukocyte damage of new device designs 
to enable the development of VADs with fewer side effects. Therefore, the purpose of this 
study was to: 1) develop an in vitro method for studying leukocyte microparticles in ovine 
blood that can be used by device developers during the screening of new device designs, and 
2) identify the parent cell type and activation status of the leukocyte microparticles formed in 
the CentriMag pump during in vitro testing.  
  
Ovine MPs in the CMAG 
4 
 
Methods 
Blood Preparation 
Ovine blood was collected by venepuncture using an 11 G x 44 mm stainless steel needle 
from live sheep (sourced from Ig-Innovations Ltd, Llandysul, UK, project licence (PPL) 
number 40/3538). The blood was collected into 14% Citrate Phosphate Dextrose Adenine 
anticoagulant solution and antibiotics / antimycotics. Ovine venepuncture blood was used as 
opposed to abattoir blood  previously [33] due to the poor quality of the blood as a result of 
the release of mechanically fragile young erythrocytes from the spleen [34]. 
Automated Haematology Analysis 
Complete blood counts were measured using the veterinary analyser Abacus Jr Vet 5 
(Diatron, Budapest, Hungary).  
Device Operation and Specifications 
The extracorporeal ventricular assist device CentriMag® CP (Abbott Vascular, Santa Clara, 
CA, USA) was tested using an in vitro testing circuit under constant haemodynamic 
conditions using three different operating conditions: herein called standard, low flow, and 
high speed. The standard operating conditions have been described in detail elsewhere [13] 
and followed the American society for testing and materials (ASTM) standards [35, 36]. 
Briefly, the flow rate was 5 ± 0.25 L/min, the differential pressure across the pump was 
adjusted using a custom-made clamp to 100 ± 3 mmHg, and the speed was 2,200 rpm. The 
low flow condition differed by using a flow rate of 1 ± 0.25 L/min, and the high speed 
condition differed by using a speed of 3,300 rpm.  
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Haemolysis 
One ml blood samples were collected hourly and centrifuged at 4700 x g for 7 min. The 
plasma supernatant (100 µl) was transferred from each aliquot into a deep well 96-well plate 
(StarLabs, Milton Keynes, UK) and diluted with 1 ml 0.1% Na2CO3 solution (Sigma-Aldrich, 
Poole, UK). 170 µl diluted plasma was transferred into a 96-well flat bottom plate (ELISA 
plate, Greiner Bio-One, Stonehouse, UK) and the absorbance was measured at three 
wavelengths: 380, 415, and 450 nm (POLARstar Omega, BMG LABTECH Ltd., Aylesbury, 
UK). The plasma-free haemoglobin (pfHb) was calculated by the Harboe direct 
spectrophotometric method (Eq. (1)) as described [37].  
(1) 𝑝𝑓𝐻𝑏 (
𝑔
𝐿
) = (167.2 𝑥 𝐴415 − 83.6 𝑥 𝐴450 − 83.6 𝑥 𝐴380) × (
1
1000
) 𝑥 (1/
𝑉𝑜𝑙𝑝𝑙𝑎𝑠𝑚𝑎
𝑉𝑜𝑙𝑁𝑎2𝐶𝑂3
) 
The normalized index of haemolysis (NIH) was calculated as described by (2) [36].  
𝑁𝐼𝐻 (
𝑔
100 𝐿
) =  ∆𝑝𝑓𝐻𝑏 × 𝑉 ×
100 − 𝐻𝑡
100
×
100
𝑄 × 𝑇
 
Where: 
NIH = normalized index of haemolysis (g/100L) 
ΔpfHb = increase of plasma free haemoglobin concentration (g/L) over the sampling time 
interval 
V = Circuit volume (L)  
Q = Flow rate (L/min) 
Ht = Haematocrit (%) 
T = Sampling time (min) 
 
(1) 
(2) 
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Flow Cytometry 
Sample Treatment and Reagents 
Leukocyte Microparticles 
Blood samples from time points 5, 120, 240, and 360 min were stained with CD45-PE 
(Thermo Fisher Scientific, Gloucester, UK) for 30 min on ice in the dark. The red blood cells 
were lysed by adding EasyLyse (1:20 with dH2O, DAKO, Alere, Cheshire, UK), followed by 
vortexing and 15 min incubation at room temperature in the dark. Necrotic cells were stained 
with 7AAD solution (eBioscience, Hatfield, Ireland, UK) at room temperature in the dark for 
15 min before acquisition. As a positive control for 7AAD staining of dead cells, 1 ml 
baseline blood was treated with Staurosporin solution (Sigma-Aldrich) at room temperature 
for at least 4 h prior to staining with CD45-PE and 7AAD. Untreated blood was single-
stained with CD45-PE and was used to set the 7AAD-gate.  
Leukocyte Activation 
Blood samples from time points 5, 120, 240, and 360 min were stained with a panel including 
activation and lineage markers. The antibodies were used according to manufacturer’s 
instructions: anti-CD11b-FITC (AbD Serotec, Oxford, UK), anti-CD21-PE (AbD Serotec) 
[38], anti-CD14-BDV500 (BD Bioscience, Oxford, UK), and anti-HLA-DR-PE-Cy7 
(eBioscience). CD11b and HLA-DR were chosen based on their clinical relevance in 
monitoring of systemic inflammation response caused by cardiopulmonary bypass pumps 
(CPB). CD11b is part of the β2 integrin CR3 (complement receptor 3; αMβ2; Mac-1; 
CD11b/CD18) [39] and is expressed on neutrophils, monocytes, and NK cells [40]. CD11b is 
upregulated on activated neutrophils in CPB patient blood [41] and has been suggested as a 
predictive marker of acute renal injury in this patient group [42]. Increased HLA-DR 
expression is a sign of T cell activation, and HLA-DR is upregulated on T cells in patients 
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suffering from dilated cardiomyopathy [43]. On the contrary, HLA-DR expression on 
lymphocytes is decreased by CPB [41], so it is unclear how T cells might respond to the 
VAD. HLA-DR is also decreased on monocytes after CPB [44-46]. CD14 was first identified 
on the surface of monocytes and macrophages [47]. Although recent evidence shows its 
expression is not restricted to myeloid cells [48], it was chosen because it is conventionally 
used as a monocyte marker for flow cytometry [49]. CD21 was chosen because of its use as 
an ovine B cell marker, targeting a subset of ovine B cells [50, 51]. Samples were vortexed 
and incubated on ice for 30min in the dark. EasyLyse (1:20 with dH2O) was added to the 
samples which were immediately vortexed and incubated for 15 min at room temperature in 
the dark to lyse the red blood cells. Antibody-capture (AbC) beads (Thermo Fisher Scientific) 
were single-stained and used as compensation controls. Fluorescence-minus-one (FMO) 
controls were used for all antibodies by staining samples subjected to medium insult (240 min 
CentriMag time point). Isotype controls, isotype-FITC (AbD Serotec, Oxford, UK) and 
isotype-PE-Cy7 (eBioscience) were used for the activation markers also using the medium 
insult samples.  
Data Acquisition 
Samples were acquired with a Navios flow cytometer equipped with three lasers (violet: 405 
nm, blue: 488 nm, red: 638 nm), the standard filter configuration, and with Navios Cytometry 
List Mode Data Acquisition and Data Analysis Software Navios Cytometer 1.2 software 
(Beckman Coulter, High Wycombe, UK). Forward scatter (FSC), side scatter (SSC), and 
fluorescent voltages were set using unstained samples and all samples were recorded for 60 
sec. Stained AbC bead samples were acquired using a gate around the beads and capturing 
10,000 events. 
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Quality Control Measures 
The instrument was maintained using daily cleaning procedures recommended by the 
manufacturer throughout the study period. The quality control used the Flow-Check and 
Flow-Set Pro Fluorospheres (Beckman Coulter) and the protocols used were set-up by the 
manufacturer’s technical support engineers. 
Data Analysis 
All data were exported and analysed using automatic compensation in Kaluza 1.5a (Beckman 
Coulter) using the data from the AbC bead samples. Data were displayed on FSC and SSC 
logarithmic axes and fluorescence displayed on bi-exponential axes [52]. 
Leukocytes were gated and displayed on a contour density dot plot with 7AAD against 
CD45-PE. The healthy cell gate was set using the Staurosporin-treated control to just outside 
the main contour of the healthy 7AAD-negative population (Supplementary Figure 1). Any 
events to the right of this border were considered 7AAD-positive necrotic leukocytes. 
Fragmented white blood cells (LMPs) still display CD45 but no longer contain DNA and 
because of their reduced size and complexity, and therefore lower side scatter, end up below 
the healthy leukocytes on an SSC axes in the gate designated MP. 
The gating strategy was drawn using the baseline samples and comparing the pattern 
differences to the pumped samples which were obvious (see for example Figure 3). FMOs for 
all antibodies, and isotype controls for the activation markers CD11b and HLA-DR, were 
prepared but did not prove useful in this lyse no wash protocol. Isotype controls were useful 
for setting the gates for the cells but not for the microparticles (Supplementary Figure 2).  
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Statistical Methods 
Averages and standard deviations were calculated for all parameters and time points. 
Leukocyte microparticles and complete blood counts were divided by the static control at 
time point 5 minutes to evaluate the relative increase or decrease caused by duration of 
pumping whilst minimising donor-to-donor variability. For haemolysis, the background 
levels observed at 5 minutes were subtracted from all other measurements. The dataset 
consisted of repeated measurements of blood samples across three pumping conditions and 4 
or 7 time points (7 for haemolysis, 4 for the other assays). Linear mixed models were used to 
analyse the dataset. The reason we used a LMM was because the observations were in the 
form of repeated measures, which introduced possible hierarchical effects. By using LMM 
we were able to allow for these. In particular, we included individual level random effects 
(intercept and rate of change) in addition to the fixed effects. Differences between the groups 
at time point 360 min were assessed with the Kruskal-Wallis test and post-hoc pairwise 
comparisons. All statistical data analysis was performed in SPSS version 22 (SPSS, Inc., 
Chicago, Illinois, US).  
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Results 
Ovine blood was run through a 2 m loop, powered by a CentriMag under 3 different testing 
conditions (Table 1).  
Haematology 
There was no significant difference in the red blood cell count for either the static or the 
pumped samples (Fig 1A). The white cells decreased significantly in the high speed condition 
(p = 0.001). Both the standard and the high speed caused a significant decrease in the 
granulocyte count compared to the static control (p = 0.006 and p < 0.001, respectively) but 
only the high speed condition caused a decrease in the monocyte count versus the static 
control (p = 0.003). There were no changes to the lymphocyte count. The platelets decreased 
significantly in both the low flow and high speed condition compared to the static (p = 0.005 
and p = 0.008, respectively).  
Haemolysis 
The pfHb levels for all testing conditions increased over time as expected (Fig 1B). The 
lowest pfHb levels were observed in the tests run at low flow, with pfHb measured at 0.7 ± 
0.6 mg/dL at 6 hours.  The highest levels of pfHb were observed in the tests run at high 
speed; pfHb measured at 7.3 ± 5.0 mg/dL at 6 hours, which was significantly different 
compared to the static control (p < 0.001).  
Leukocyte microparticles 
All pumping conditions caused a significant increase in CD45
+
 LMPs compared to the static 
control (low flow: p = 0.005, standard: p = 0.004, high speed: p < 0.001; Fig 1C). An 
example of the flow cytometry data from the high speed condition over time is shown (Fig 2). 
The antibodies were tested on baseline blood to confirm that they could detect the target 
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parent cells (Supplementary Figure 3). CD14-BDV500 detected granulocytes (high 
SSC/CD14
dull
), and monocytes (medium-high SSC/CD14
+
). CD21-PE stained a B cell subset 
(medium SSC/CD21
+
). CD11b-FITC mainly stained granulocytes, monocytes, and a subset 
of lymphocytes. HLA-DR-PE-Cy7 targeted monocytes and a subset of lymphocytes. Gated 
medium-high SSC/CD14
+
 monocytes were CD11b
+
 and about 60% also expressed HLA-DR. 
Of the CD21
+
 B cells, around 50% were HLA-DR
+
/CD11b
-
, and approximately 40% were 
double positive. 
Characterisation of LMPs 
LMPs generated during pump testing expressed CD11b and/or HLA-DR (Figure 3). Three 
subpopulations could be identified: CD11b
bright
HLA-DR
+
, CD11b
dull
HLA-DR
+
, and 
CD11b
bright
HLA-DR
-
 (Fig 4A). All three populations were negative for both CD14 and CD21 
(Fig 4B), so are unlikely to be derived from monocytes or the CD21
+
 B cell subset. On 
specifically seeking CD14
+
 or CD21
+
 LMPs there were none detectable (Supplementary 
Figure 4). Since HLA-DR expression was restricted to the monocyte/lymphocyte side scatter 
area (Fig 3C), the parental lineage is unlikely to be granulocytes and we propose T cells or 
CD21
-
 B cells as the most likely parental lineages for the CD11b
dull
HLA-DR
+
 LMPs. The 
parental lineage for the CD11b
bright
HLA-DR
-
 population is most likely granulocytes, due to 
their high CD11b expression (Fig 3B) and lack of HLA-DR (Fig 3C). The small 
CD11b
bright
HLA-DR
-
 population could be a further activated subset from either of the 
granulocyte or lymphocyte MP populations, as both activated T cells can increase their 
CD11b expression [53], and activated neutrophils can increase their HLA-DR expression 
[54]. 
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Influence of Pumping Condition on Activated LMP Production 
The standard and the high speed condition caused a significant increase in the 
CD11b
bright
HLA-DR
-
 LMPs versus the static control (p = 0.027 and p < 0.001, respectively) 
(Figure 4C). The high speed also caused a significant increase for the CD11b
bright
HLA-DR
+
 
LMPs compared to the static control (p < 0.001) (Figure 4D). The CD11b
dull
HLA-DR
+
 LMPs 
significantly increased during all pumping conditions compared to the static control (p < 
0.001) (Figure 4E). Finally, at 360 min, the high speed condition caused significantly more 
CD11b
bright
HLA-DR
-
 LMPs compared to CD11b
dull
HLA-DR
+
 LMPs (p = 0.002). 
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Discussion 
To the best of our knowledge this is the first study to describe a four colour flow cytometry 
panel for ovine leukocytes; previous studies have used single or two-colour approaches [55-
58]. It is also the first time LMPs displaying activation markers have been shown to be 
generated during in vitro VAD testing, and the first time LMPs have been demonstrated in 
vitro using ovine blood. This study also represents the first ovine blood damage profile for 
the CentriMag operated under standard conditions (as defined by ASTM [35, 36]). The panel 
described herein can be used to detect differences in LMP generation due to shear stress as 
demonstrated by pumping whole blood in the CentriMag, a suggested benchmark for in vitro 
VAD-testing [13], at different operating conditions. The antibodies used were chosen on two 
criteria: 1) directly conjugated to fluorochromes for replicability and uptake by other users, 
and 2) cross reactivity to ovine, bovine, and human blood cells, to yield a translational 
research tool suitable for device developers using animals in the pre-clinical phase and then 
progressing to clinical studies. 
Similarly to our previously published bovine CentriMag blood damage profile [13], the 
standard condition did not cause any significant differences to ovine total red cell, white cell, 
or platelet counts. However, now we also studied the leukocyte subsets, and show that the 
standard condition caused a significant reduction in the granulocyte count. Perhaps because 
the lymphocytes are the most prevalent white blood cell type in bovine and ovine blood [59], 
and lymphocyte counts remained constant in this ovine blood study, they mask the decreasing 
granulocytes levels when only the total white blood cell count is measured.  
The high speed condition caused a reduction in both granulocyte and monocyte counts, but 
lymphocytes remained constant. This reflects either the resilience of lymphocytes or their 
abundance in the ovine circulation [59]. Consideration of lymphocyte subsets and/or a higher 
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resolution method such as absolute counting using flow cytometry [33] might be required to 
assess any decrease in lymphocyte cell numbers. Both the low flow and the high speed 
conditions significantly decreased platelet counts. Platelet activation is caused by both an 
increase in residence time (as in the low flow condition)[60], and by high shear stress [61, 62] 
which could lead to lysis and/or aggregation and the observed reduction in numbers. 
Interestingly, our previous study of bovine blood using the extracorporeal RotaFlow and the 
intracorporeal VentrAssist pumps observed an increase in platelet numbers [12]. This 
increase was hypothesised to be due to leukocyte microparticles being falsely detected as 
platelets by the haematology analyser due to the concomitant decrease in leukocytes and 
increase in CD45
+
 LMPs [12]. Although the high speed condition in this current study caused 
a reduction in leukocytes and an increase in CD45
+
 LMPs, there was no increase in platelets. 
This could be due to different haematology analysers being used in the two studies (CELL-
DYN Ruby versus Abacus Jr Vet 5).  
The haemolysis data showed evidence of increased resilience of ovine venepuncture versus 
bovine abattoir erythrocytes to the effects of shear. Levels of pfHb obtained with ovine blood 
were one quarter of those obtained in bovine blood after 360 minutes pumping in the 
CentriMag at the standard condition (2.5 ± 1.0 versus 10 ± 1.5 mg/dL), with mgNIH roughly 
one third in ovine compared to bovine blood (0.38 ± 0.15 compared to 1.10 ± 0.5 mg/100L) 
[13]. In our previous multispecies comparison study in which we evaluated the response to 
shear caused by a rheometer, we also observed greater haemolysis in bovine abattoir 
compared to ovine venepuncture blood at high shear (75 versus 50 mg/dL at 8000 s
-1
, 
respectively), although this difference was not statistically significant [34].  
The standard condition in this study caused a significant increase in ovine CD45
+
 LMPs, as 
previously observed in bovine blood [13]. In addition, the CD45
+
 LMPs significantly 
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increased in the low flow and the high speed conditions as well. We have confirmed the LMP 
identity in a previous study [12], where we showed that: CD45
+
 LMPs were a fraction of the 
size compared to CD45
+
 leukocytes using imaging cytometry; we showed microparticles, 
morphologically different from platelets, in association with leukocytes using scanning 
electron microscopy; and we showed that, when using bovine activated platelet marker 
GC5A, the FSC/SSC region co-habited by microparticles and platelets consists of 3 separate 
populations: CD45
+
 LMPs, activated GC5A
-
 platelets, and resting GC5A
+
 platelets. 
In this study, three novel ovine LMP populations were identified: CD11b
bright
HLA-DR
+
, 
CD11b
dull
HLA-DR
+
, and CD11b
bright
HLA-DR
-
. These were all negative for CD14 and CD21, 
suggesting they are not derived from monocytes or the CD21
+
 B cell subset. However, it is 
possible that as there are relatively few monocytes in ovine blood [59], monocyte-derived 
LMPs might simply be relatively rare and undetectable. The remaining major cell types are 
neutrophils, T cells, and CD21
-
 B cells. Neutrophils express CD11b, and have been shown to 
produce CD11b
+
 MPs when activated in vitro [63-65]. Considering that the granulocyte cell 
count (Fig 1) and the CD11b
bright
HLA-DR
-
 frequency (Fig 4C) were both the most affected 
by the high speed condition, this further supports that the CD11b
bright
HLA-DR
-
 MPs are of 
neutrophil origin. Excluding granulocytes (CD11b
bright
), and monocytes (CD14
+
), T cells, or 
CD21
-
 B cells are the most likely parent of the CD11b
dull
HLA-DR
+
 MPs. That granulocytes 
and T cells would be the cell types most affected in the VAD in vitro, is supported by clinical 
evidence showing the activation of both granulocytes and T cells in VAD-patients [5, 7, 8].  
This study shed light on two important aspects of leukocyte MPs in relation to VADs. Firstly, 
it showed that CD11b
+
 MPs are generated in VADs, which could have implications for pump 
thrombosis. Low levels of CD11b
+
 LMPs are a risk factor in patients suffering non-ST 
elevated acute coronary syndrome, as low levels are associated with a higher number of 
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occluded arteries, higher number of >50% stenosis, higher number of stenosed arteries, and 
higher frequency of recurring cardiovascular events, [66]. The decline in CD11b
+
 LMPs is 
suggestive of their consumption in the occlusions, since CD11b
+
 levels negatively correlate 
with thrombus weight in a mouse model [19]. The mechanism is likely to be through αMβ2 
interaction with resting platelets, causing them to become activated [65].  
Secondly, it showed that different LMP subtypes respond differently to changes in operating 
conditions. The CD11b
dull
HLA-DR
+
 LMPs were sensitive to pumping and significantly 
increased regardless of the operating conditions. However, they did not respond to a further 
increase in speed. In contrast, the levels of CD11b
bright
HLA-DR
-
 LMPs were not significantly 
different from the static control in any other condition than the high speed so are seemingly 
more affected by increasing speed than the CD11b
dull
HLA-DR
+
 LMPs. Hence, the 
CD11b
dull
HLA-DR
+
 LMPs show potential as a positive control for pumping versus static 
samples, and the CD11b
bright
HLA-DR
-
 LMPs may be able to differentiate between the effects 
of pump designs on LPM generation if the pumps differ in shear stress. The different 
responses to the operating conditions further supports that these LMPs are of different 
cellular origins. In vitro studies of human leukocytes under shear stress have revealed that the 
fluid shear response is not uniform among all cells. At low shear stress levels (0.2 dyn/cm
2
 
for 5 min) about 33% of leukocytes respond with pseudopodia projection [67]. These first 
responders could be lymphocytes since they make up 17-48 % of the human leukocyte count, 
whereas neutrophils make up 40-75% [68]. The number of human leukocytes responding to 
shear stress increases with each 1 dyn/cm
2 
[67]. This could be the neutrophils as they have 
been described to display a dose-response relationship with both shear magnitude and time in 
vitro using a cone-and-plate viscometer, with L-selectin shedding as the measure [69]. Lastly, 
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the migration of human T cells and neutrophils in vitro also differs with T cells migrating 
against the fluid flow and neutrophils migrating with it [70]. 
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Study Limitations 
One study limitation was to find antibodies that target ovine blood cells. For example, there is 
no ovine platelet lineage marker that is not affected by activation which is why platelet MPs 
were not studied. This also means we cannot analyse the potential platelet contamination 
within the leukocyte MP population. However, a confirmatory experiment using human 
blood double-stained with platelet and leukocyte lineage markers CD41 and CD45, 
respectively, pumped using the ’high speed’ protocol, showed that within the CD45+ MP 
population, there is a 10% contamination of double-positive platelet aggregates 
(Supplementary Figure 5). Thus, if the assay is used with human blood, an initial platelet-
discrimination gate can be set to exclude platelet-MP aggregates from further analysis steps, 
if desired. 
In addition, there is no directly conjugated anti-ovine granulocyte antibody available to 
confirm that the CD11b
bright
 MPs were of neutrophil origin. For future studies, in-house 
conjugation of the granulocyte-monocyte targeting antibody clone, DH59B [56], could be 
used in combination with anti-CD14 to distinguish the granulocyte (DH59B
+
CD14
+
) and 
monocyte  (DH59
bright
CD14
bright
) MPs.  
Although there is a vast amount of literature describing that MPs can be identified using 
lineage markers [21, 71-73], a couple of studies have described contradictory results. 
Monocyte and lymphocyte MPs, in particular B cell MPs, have been described to lack lineage 
markers [74, 75]. In addition, human malignant B cell MPs, but not T cell MPs, have been 
described to express HLA-DR [75], hence the CD11b
dull
HLA-DR
+
 LMPs could be B cell 
MPs that are not expressing CD21; this remains to be proven.  
The method described herein was developed as a whole blood wash-no-lyse protocol in order 
to fit around the routine haemolysis procedures of a device testing lab. As per the ASTM 
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standard, haemolysis testing should be carried out on fresh blood for a total of 6 hours [36]. 
In practice, this means that any samples collected from such a test will be available in the 
evening. We deemed an MP isolation method including several centrifugation steps would be 
too time-consuming for it to be practical to do in addition to a haemolysis test for most device 
developers. Thus, we opted for a rapid whole blood staining protocol to make it user friendly.  
Lastly, conventional flow cytometric methods use standardisation beads to define the initial 
FSC/SSC scatter gate for further MP analysis. Although we did not use such beads, the 
method is fully compatible with beads as exemplified by a subsequent acquisition of 
Megamix beads using the same acquisition protocol. When displaying the MP population in a 
Megamix gate created around the FSC/SSC of beads 900 nm and smaller, 92% of the CD45
+
 
MP population was within the gate (Supplementary Figure 6). Thus, an additional Megamix 
bead gate could be introduced, if desired. 
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Conclusion 
This first report of the blood damage profile of ovine blood exposed to the CentriMag pump 
shows that ovine venepuncture blood may potentially be more resilient than bovine abattoir 
blood to shear stress. This is supported by our previous multispecies rheometry study [34]. As 
expected, the high speed condition was the most detrimental regarding all parameters. This 
condition caused a significant decrease in total leukocytes, granulocytes, monocytes and 
platelets; an increase in pfHb; and an increase in CD45
+
 LMPs, and, using a 4-colour panel 
for ovine leukocytes for the first time, an increase in three novel LMP populations: 
CD11b
bright
HLA-DR
+
, CD11b
dull
HLA-DR
+
, and CD11b
bright
HLA-DR
-
.  
We propose that this multicolour panel can be used by device developers to test and develop 
VADs with better blood handling capacity for reduced side effects. Our next step is to repeat 
this study in bovine blood using several device types and to expand the flow cytometry panel 
used to include granulocyte and T cell markers based on the results presented herein. This 
will confirm if the panel is useful for monitoring LMP formation during in vitro testing in 
bovine blood and promote its further adoption by the industry. It will also enable us to 
identify the parental lineage of LMPs and undertake pump comparison testing. This study 
also highlights the need to better understand the formation and functional effects of 
circulating LMPs in humans implanted with VADs. 
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Tables 
Table 1. Operating conditions 
 Low flow Standard High speed 
Speed (rpm) 2200 ± 0 2200 ± 82 3300 ± 0 
Flow (L/min) 1.00 ± 0.03 5.03 ± 0.08 4.96 ± 0.06 
Pressure (mmHg) 105.29 ± 1.91 82.98 ± 4.59 212.23 ± 19.14 
mgNIH at 360 min (mg/100L) 1.05 ± 0.89 0.38 ± 0.15 2.82 ± 2.80 
Baseline Hct (%) 30.33 ± 2.57 30.78 ± 1.49 29.25 ± 3.88 
Baseline Hb (g/L) 116.27 ± 15.55 116.03 ± 15.05 108.11 ± 12.36 
Sample size (n) 4 5 5 
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Figure Legends 
Figure 1. Haematology, Haemolysis, and Leukocyte Microparticles Generated in the 
Centrimag Under Different Conditions. 
Ovine blood was diluted to a haematocrit of 30 ± 2% using PBS, loaded into the CentriMag 
loop and run at either low flow: 2,200 rpm, 1 L/min (n = 3), standard conditions: 2,200 rpm, 
5 L/min (n = 5), or high speed: 3,300 rpm, 5 L/min (n = 5). A 500 mL bag of ovine blood was 
left in the +37°C water bath as a static control. Blood samples were removed every hour for 6 
hours. A. Average complete cell counts from blood samples run in triplicate for erythrocytes, 
leukocytes, platelets, granulocytes, monocytes, and lymphocytes for each time point. B. 
Plasma free haemoglobin. C. Number of CD45 positive (CD45
+
) microparticles. 
Figure 2. Baseline Blood Characterisation.  
Ovine whole blood stained with antibodies targeting CD14, CD21, CD11b, and HLA-DR. A. 
Granulocytes have high side scatter (SSC) and are CD14
dull
. Monocytes (gated) have 
medium-high SSC and are CD14
+
. B. Some B cells have medium SSC and are CD21
+
. C. 
CD11b is mainly expressed by granulocyte and monocytes and a subset of lymphocytes. D. 
HLA-DR expression is restricted to monocytes and a subset of lymphocytes. E. Monocytes 
are CD11b
+
 and around 60% are HLA-DR
+
. F. Of CD21
+
 B cells, about 50% are HLA-
DR
+
/CD11b
-
, and approximately 40% are double positive. 
Figure 3. Scatter Profile and MP Formation During High Speed Pump Setting. 
Ovine whole blood pumped in the CentriMag (CMAG) at high speed (3,300 rpm) for 5, 120, 
240, and 360 min and compared to baseline. The blood was stained with antibodies targeting 
CD14, CD21, CD11b, and HLA-DR. FSC / SSC: there is an initial increase in scatter 
followed by a rapid decline during pumping. CD11b
+
 and HLA-DR
+
 MPs have low SSC and 
increase in frequency with pumping time.  
Figure 4. LMP populations expressing activation markers. 
Ovine whole blood pumped in the CentriMag (CMAG) at high speed (3,300 rpm) for 360 
min. The blood was stained with antibodies targeting CD14, CD21, CD11b, and HLA-DR, 
and MPs expressing CD11b and/or HLA-DR were gated. A Boolean gate named Active MPs 
was created (CD11b
+
 OR HLA-DR
+
 MPs) and displayed. A. Active MPs form three distinct 
populations when displayed on CD11b versus HLA-DR axes. B. The three populations are 
CD14
-
/CD21
-
, and therefore likely to be generated by granulocytes (CD11b) and T cells or 
CD21
-
 B cells (HLA-DR) based on the baseline cell surface marker expression 
(Supplementary Figure 3). 
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Supplementary Figure Legends 
 
Supplementary figure 1: Gating strategy for the determination of leukocyte 
microparticles using staurosporine control. Ovine blood (1 ml, baseline sample) treated 
with 3 μM Staurosporin solution at room temperature for at least 4 h prior to staining with 
CD45-PE and 7AAD. A. Forward and side scatter plot (log scale) showing the location of 
leukocytes. B. CD45-PE and side scatter indicating leukocytes as CD45+ events. C. The 
CD45+ events expressed on a 7AAD and side scatter plot to show healthy, necrotic, and 
CD45+ microparticles (MPs). 
 
Supplementary figure 2: Fluorescence-minus-one (FMO) and isotype controls. Ovine 
blood entered into the CentriMag loop and run at 3,300 rpm, 5 L/min (high speed condition). 
Samples were obtained after 4 hours and stained with CD14-BDV500, CD21-PE, CD11b- 
FITC, and HLA-DR-PE-Cy7 (ALL ABS). In addition, FMO controls were created by 
omitting one of the antibodies (i.e. CD14-FMO does not contain CD14-BDV500 but the three 
other antibodies). Isotype controls were created by swapping either CD11b-FITC or HLADR- 
PE-Cy7 for its isotype control as specified by the manufacturer. Gates were set based on 
the baseline sample (see Figure 2) and applied to the samples to assess the usefulness of the 
FMO and isotype controls. 
 
Supplementary figure 3: Comparison of leukocyte microparticle generation over time 
between static control and CentriMag. Ovine blood was entered into the CentriMag loop 
and run at 3,300 rpm, 5 L/min (high speed condition). A 500 mL bag of ovine blood was left 
in the +37°C water bath as a static control. Blood samples were removed every 2 hours and 
stained with CD45-PE and 7AAD. 
 
Supplementary figure 4. Search for CD14+ and CD21+ microparticles. Ovine blood was 
entered into the CentriMag loop and run at 3,300 rpm, 5 L/min (high speed condition). 
Samples were removed every 2 hours and stained with CD11b-FITC, CD14-BDV500, CD21- 
PE, and HLA-DR-PE-Cy7. The low side scatter (SSC) region was analysed to see if the 
number of CD14+ or CD21+ events increased over time. 
 
Supplementary figure 5. Analysis of contaminating platelets. Human blood was 
entered into the CentriMag loop and run at 3,300 rpm, 5 L/min (high speed condition). 
A sample was removed at 6 hours and stained with CD45-PE, CD41-FITC, and 7AAD. A-C) The 
CD45+ MPs were gated as previously described. D) The contaminating CD41+ platelet events 
within the CD45+ MP population were assessed. 
 
Supplementary figure 6. CD45+ LMP method compatibility with Megamix Beads.  
Megamix beads, 0.5, 0.9 and 3.0 µm in size, were acquired using the standard ovine CD45+ LMP 
acquisition protocol on the Navios flow cytometer and compared to a previously acquired ovine 
CD45-PE stained blood sample obtained at 6 hours from the CentriMag when operated at the 
high speed (3,300 rpm, 5 L/min) condition. A-C) The CD45+ LMPs were gated as previously 
described. D) A ‘microparticle’ gate was created to include beads ≤ 0.9 µm on a FSC/SSC scatter 
plot. E) The CD45+ LMPs were displayed on a FSC/SSC scatter plot to assess whether or not 
they fall within the ‘microparticle’ gate (92% compatibility). 
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